JPRN-UMIN000023897
Completed
Phase 2
Prospective study of evaluating the efficacy and safety of Radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases - Prospective study of Radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases
ational Hospital Organization Saitama Hospital0 sites20 target enrollmentSeptember 1, 2016
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- castration-resistant prostate cancer with bone metastases
- Sponsor
- ational Hospital Organization Saitama Hospital
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) organ metastases excluding bone metastases 2\) active concomitant malignancy 3\) inflammatory bowel disease (Crohn's disease or ulcerative colitis) 4\) use of chemotherapy with myelosuppresion reaction at the same time 5\) difficult to participate with the trial, having mentel disorder or psychiatric symptoms 6\) immuno\-suppression treatment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
N/A
A prospective study to evaluate the efficacy and safety of pregabalin for triweekly abraxane-induced peripheral neuralgiaBreast cancerJPRN-UMIN000006987Kinki University Faculty of Medicine30
Recruiting
N/A
A prospective study to evaluate the efficacy and safety of a new knife in endoscopic treatment for gastric neoplasmNeoplasmsKCT0005164Asan Medical Center100
Not Yet Recruiting
N/A
effect of alpha blockers in benign prostatic hyperplasiaHealth Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptomsCTRI/2021/04/033122DR I C VIGNESH RAJA
Recruiting
Phase 2
STUDY TO EVALUATE THE EFFECT AND SAFETY OF AN AYURVEDIC DRUG (URAL CAPSULE) IN RENAL STONESHealth Condition 1: null- Patients suffering from Stones in Kidney, Ureters and Urinary BladderCTRI/2018/07/014706ational Institute of Ayurveda
Active, Not Recruiting
Phase 2
A prospective study of investigating the efficacy of FOLFIRI plus Aflibercept as a 2nd line therapy after progression during FOLFOXIRI plus Bevacizumab in unrescetable / metastatic colorectal cancer (CRC) patients.Colorectal CancerJPRN-jRCTs071190003Oki Eiji35